Last reviewed · How we verify
disodium EDTA
Disodium EDTA is a chelating agent that binds and removes heavy metals and excess divalent cations from the bloodstream.
Disodium EDTA is a chelating agent that binds and removes heavy metals and excess divalent cations from the bloodstream. Used for Lead poisoning (plumbism), Hypercalcemia, Heavy metal toxicity (cadmium, zinc).
At a glance
| Generic name | disodium EDTA |
|---|---|
| Also known as | EDTA, Edetic Acid, Calcium, Sodium Salt, Edetate Disodium Calcium, chelation therapy |
| Sponsor | Mt. Sinai Medical Center, Miami |
| Drug class | Chelating agent |
| Target | Divalent metal cations (Pb²⁺, Cd²⁺, Ca²⁺, Zn²⁺) |
| Modality | Small molecule |
| Therapeutic area | Toxicology / Nephrology |
| Phase | FDA-approved |
Mechanism of action
EDTA (ethylenediaminetetraacetic acid) forms stable complexes with metal ions such as lead, cadmium, and calcium, facilitating their urinary excretion. It is used clinically to treat heavy metal poisoning and hypercalcemia by reducing circulating levels of these ions.
Approved indications
- Lead poisoning (plumbism)
- Hypercalcemia
- Heavy metal toxicity (cadmium, zinc)
Common side effects
- Nephrotoxicity / acute kidney injury
- Hypocalcemia
- Hypomagnesemia
- Zinc depletion
- Infusion site reactions
Key clinical trials
- Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) (PHASE2)
- Skin Barrier Function and Inflammation in Aging: The BIA Study (PHASE4)
- Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (PHASE1)
- Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC) (PHASE2)
- ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 (PHASE3)
- A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (PHASE1, PHASE2)
- Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions (NA)
- A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- disodium EDTA CI brief — competitive landscape report
- disodium EDTA updates RSS · CI watch RSS
- Mt. Sinai Medical Center, Miami portfolio CI